S-Ketamine in the treatment of depressive emergencies: a cases series of patients in a suicidal crisis
European Psychiatry June 1, 2022 B. Baune, Z. Susam, V. Falcone et al.
Intranasal S-ketamine (Spravato) can be safely and effectively administered in an acute psychiatric emergency setting to treat depressive crises in patients with treatment-resistant major depressive disorder who have severe suicidal ideation. In a case series of 10 patients (70% female, mean age 49.5 years), average MADRS scores dropped from 37 pre-treatment to 18 post-treatment, and BDI scores dropped from 39 to 24. Side effects such as dissociation were short-lived.